Myeloid neoplasms with erythroid or megakaryocytic differentiation include pure erythroid
leukemia, myelodysplastic syndrome with erythroid features, and acute megakaryoblastic
leukemia (FAB M7) and are characterized by poor prognosis and limited treatment options.
Here, we investigate the drug sensitivity landscape of these rare malignancies. We show
that acute myeloid leukemia (AML) cells with erythroid or megakaryocytic differentiation
depend on the antiapoptotic protein B-cell lymphoma (BCL)-XL, rather than BCL-2, using …

Myeloid neoplasms with erythroid or megakaryocytic differentiation include pure erythroid
leukemia (PEL), myelodysplastic syndrome (MDS) with erythroid features, and acute
megakaryoblastic leukemia (FAB M7) and are characterized by poor prognosis and limited
treatment options. Hypothesizing that the distinct lineage of acute myeloid leukemia (AML)
with erythroid or megakaryocytic differentiation may confer specific vulnerabilities, we sought
to identify selective dependencies in these rare subtypes in comparison with other AML …